Abstract

There is emerging evidence to suggest that brain natriuretic peptide (BNP) is elevated after acute brain injury, and that it may play an adaptive role in recovery through augmentation of cerebral blood flow (CBF). Through a series of experiments, we tested the hypothesis that the administration of BNP after different acute mechanisms of central nervous system (CNS) injury could improve functional recovery by improving CBF. C57 wild-type mice were exposed to either pneumatic-induced closed traumatic brain injury (TBI) or collagenase-induced intracerebral hemorrhage (ICH). After injury, either nesiritide (hBNP) (8 \( \mu \)g/kg) or normal saline were administered via tail vein injection at 30 min and 4 h. The mice then underwent functional neurological testing via rotorod latency over the following 5 days and neurocognitive testing via Morris water maze testing on days 24–28. Cerebral blood flow (CBF) was assessed by laser Doppler from 25 to 90 min after injury. After ICH, mRNA polymerase chain reaction (PCR) and histochemical staining were performed during the acute injury phase (<24 h) to determine the effects on inflammation. Following TBI and ICH, administration of hBNP was associated with improved functional performance as assessed by rotorod and Morris water maze latencies \( (p < 0.01) \). CBF was increased \( (p < 0.05) \), and inflammatory markers (TNF-\( \alpha \) and IL-6; \( p < 0.05) \), activated microglial (F4/80; \( p < 0.05) \), and neuronal degeneration (Fluoro-Jade B; \( p < 0.05) \) were reduced in mice receiving hBNP. hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury.

Key words: brain natriuretic peptide; cerebral blood flow; intracerebral hemorrhage; nesiritide; neuroinflammation; neuroprotection; traumatic brain injury

Introduction

Brain natriuretic peptide (BNP) was first discovered in the porcine central nervous system (Sudoh et al., 1988) and has since been established to be a major determinant for prognosis in patients with myocardial injury and congestive heart failure (Mukoyama et al., 1991; Rubattu et al., 2008). BNP is believed to play an important role in the regulation of electrolytes and water balance through its natriuretic effects, and inhibition of the renin-angiotensin-aldosterone system with regulation of vasculature permeability. In addition, BNP inhibits the activity of the sympathetic nervous system by interacting with baroreflex control, thereby modulating sympathetic tone (Luchner and Schunkert, 2004). In particular, it appears that BNP may have sympatholytic effects, providing a major advantage in the setting of congestive heart failure (Kasama et al., 2004).

Recent evidence suggests that BNP may also play an adaptive role following acute brain injury. For example, BNP elevations have been described in a pre-clinical model of middle cerebral artery occlusion (Brosnan et al., 1999), and in clinical studies of traumatic brain injury (TBI) (Kirchhoff et al., 2006; Lu et al., 2008; Powner et al., 2007; Sviri et al., 2006), stroke (Di Angelantonio et al., 2007; Jensen et al., 2006; Laskowitz et al., 2009; Modrego et al., 2008; Montaner et al., 2008; Nakagawa et al., 2005), and subarachnoid hemorrhage (McGirt et al., 2004). Although the role of BNP following brain injury remains unclear, potential beneficial effects may be related to its anti-inflammatory and vasoactive properties. In this study we test the hypothesis that BNP may play a neuroprotective role by administering nesiritide, a recombinant form of naturally-occurring B-type human natriuretic peptide, in murine models of intracranial hemorrhage (ICH) and TBI, and assessing vestibulomotor and neurocognitive...
performance after injury. Given the known effects of BNP on blood flow and inflammation, we evaluated whether functional effects were associated with improved post-injury cerebral blood flow (CBF) and/or reduced neuroinflammatory responses.

**Methods**

*Experimental design and matrix*

We evaluated the effects of nesiritide treatment after two separate brain injury models: closed head injury and ICH. Several cohorts of animals were utilized in each injury model. For both models we determined functional outcomes via rotorod and Morris water maze (MWM) testing. After TBI, we evaluated CBF by laser doppler and changes in serum sodium in the acute phase of injury. After ICH, we evaluated the CNS inflammatory response by mRNA polymerase chain reaction (PCR) and magnetic resonance imaging, microglial recruitment and activation by F4/80 staining, and neuronal degeneration by Fluoro-Jade B staining in the subacute phase of the injury. The experimental matrix is shown in Figure 1.

*Traumatic brain injury model*

Our murine injury model (Lynch et al., 2005) was adapted from a previously described model of closed cranial trauma for the rat (Foda and Marmarou, 1994). Male 10- to 12-week-old C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were used in these experiments. Prior to injury, the mice were randomized to treatment or vehicle groups. The trachea was intubated after anesthesia induction with 4.6% isoflurane, and the lungs were mechanically ventilated with 1.6% isoflurane in 30% oxygen/70% nitrogen. Rectal temperature was maintained at 37°C ± 0.2°C. The animal was positioned in a stereotactic device, the scalp was incised, and the skull exposed. A concave 3-mm metallic disc was glued to the skull immediately caudal to the bregma. A 2.0-mm-diameter pneumatic impactor (Air-Power, Inc. High Point, NC) was used to deliver a single midline impact to the disc surface. The impactor was discharged at 6.8 ± 0.2 m/sec with a head displacement of 3 mm. After impact, the animals were allowed to recover spontaneous ventilation, and were then extubated and given free access to food and water.

*Intracerebral hemorrhage model*

Our murine injury model (James et al., 2008b) was adapted from a previously described model of ICH in rats (Rosenberg et al., 1990). Male 10- to 12-week-old C57BL/6J mice (Jackson Laboratory) were used in these experiments to avoid potential effects of age-related vasculopathy. Prior to injury, the mice were randomized to treatment or vehicle groups. The trachea was intubated after anesthesia induction with 4.6% isoflurane and the lungs were mechanically ventilated with 1.6% isoflurane in 30% oxygen/70% nitrogen. Rectal temperature was maintained at 37 ± 0.2°C by an underbody warming system. The animal’s head was secured in a stereotactic frame, local anesthetic was injected, and the scalp incised. After exposure of the skull, a burr hole was created 2 mm left lateral to the bregma, and a 0.5-mL syringe needle (Hamilton, Reno, NV) was advanced to a depth of 3 mm from the cortex. Type IV-S clostridial collagenase (Sigma, St. Louis, MO) was injected over 5 min (0.1 U in 0.4 mL NS). The incision was then closed and the animals were allowed to recover spontaneous ventilation, after which they were extubated and given free access to food and water.

*Nesiritide administration*

Prior to injury, mice were randomized to receive low-dose nesiritide (2 mg/kg), high-dose nesiritide (8 mg/kg), or vehicle (sterile saline) via tail vein injection at 30 min and 4 h. Drug and vehicle were administered in a volume of 100 mL sterile normal saline.

**FIG. 1.** Experimental matrix detailing the timing of outcome measures in each model (POD, postoperative day; PCR, polymerase chain reaction).
Neurological testing

An automated rotorod (Ugo Basile, Comerio, Italy) was used to assess the effects of therapeutic intervention on vestibulomotor function (Hamm et al., 1994) On the day prior to injury, the mice underwent two consecutive conditioning trials at a set rotational speed (16 revolutions/min) for 60 sec, followed by three additional trials with accelerating rotational speeds. The average time to fall from the rotating cylinder in the latter three trials was recorded as baseline latency. After injury, the mice underwent consecutive daily testing with three trials of accelerating rotational speed (inter-trial interval of 15 min). Average latency to fall from the rod was recorded. Mice unable to grasp the rotating rod were given a latency of 0 sec.

Morris water maze testing

The MWM (Morris 1984) was used to assess the effects of therapeutic intervention on spatial learning and memory. After injury, performance was evaluated in a black aluminum pool (105 cm in diameter, 60 cm in depth) filled with water opacified with powdered milk. The pool contained a platform (7.5 cm in diameter) submerged 1 cm below the water’s surface (25–27°C). The maze was kept in a room dedicated to behavioral testing with light and sound maintained constant throughout training and testing. Prior to injury, the mice were trained on the visible platform (1 d; the platform was flagged, located in a different quadrant for each trial to minimize quadrant habituation, and no extra-maze visual cues), and the hidden platform (4 d; the platform was submerged in the western quadrant for all trials, with several extra-maze visual cues) versions of the MWM task to habituate the mice to handling and to swimming, as well as to teach them the goal of the task, which was to escape from the water by climbing onto a platform. Such habituation and pre-training has been shown to decrease stress, which negatively impacts the performance of mice on the MWM task (Holscher, 1999). Pre- and post-injury testing followed the same protocol. Each testing day consisted of four trials per day with an inter-trial interval of 20–30 min. For each trial, the mice were placed into the pool facing the perimeter and were allowed to search for the platform for a maximum of 90 sec. If they were unable to locate the platform within the allotted time, they were guided to it and remained on the platform for 10 sec before being returned to their heated home cages. The mice were started in one of four different quadrants for each trial, with starting quadrants randomly defined each day. Latency to find the platform and swimming speed were recorded by a computerized video tracking system (KeilSoft LLC, Chapel Hill, NC).

On the final day of hidden platform testing, a probe trial was conducted to evaluate retention capabilities. The escape platform was removed from the pool and the mouse was released into the maze at a point diagonally opposite from the previous location of the platform (i.e., the eastern quadrant). The time spent searching all four and the number of crossings into the western quadrant was recorded. Post-injury MWM visible testing was conducted on day 23, and hidden platform testing was conducted daily from day 24 through day 27, with a probe trial following the last trial on day 28. Water maze testing was performed by an examiner blinded to treatment assignment.

Measurement of serum sodium

The effect of therapeutic intervention on serum sodium levels was assessed in a separate cohort of animals receiving either nesiritide or saline via tail vein injection at 30 min after TBI (n = 4 animals/group). As previously described, the mice were anesthetized, injured, and treated, after which a 0.2-mL blood sample obtained via left ventricle puncture and analyzed with an IL GEM Premier 3000 blood gas analyzer (Global Medical Instrumentation, Ramsey, MI) at 3 h after TBI to assess blood gases and electrolytes.

Laser doppler cerebral blood flow

The effect of therapeutic intervention on CBF was assessed by laser doppler flowmetry in a separate cohort of animals receiving either nesiritide or saline via tail vein injection at 30 min after TBI (n = 8 animals/group). As previously described, the mice were anesthetized, injured, and treated, after which a 1.9-mm-diameter laser doppler needle probe was placed on the skull in the left middle cerebral artery distribution (1 mm posterior and 5 mm lateral to the bregma). (Tsuehiya et al., 2003). Cortical perfusion values were recorded from 25–90 min after injury.

Magnetic resonance imaging

The effect of therapeutic intervention on ICH volume was assessed by magnetic resonance imaging (MRI) in a separate cohort of animals receiving either nesiritide or saline via tail vein injection at 30 min and 4 h after ICH (n = 6 animals/group). MRI was performed using a 7T Bruker MRI (Bruker Biospin, Newark, DE) at 4 h after injury. The animals were anesthetized via inhalation of 1.5% isoflurane in room air and cardiopulmonary parameters were monitored continuously. Core temperature was maintained at 37 ± 0.5°C via a circulating water bath. Each MRI session lasted 20 min, which was equivalent across all animal groups. Images were acquired at a 256×256 matrix and a 4-cm² field of view. A RARE sequence was performed for both T1-weighted (TE/TR = 7.5/1300) and T2-weighted (TE/TR 12/4200) imaging. Eighteen slices of 1 mm thickness were performed for entire brain coverage. As previously described (James et al., 2008a), ICH volume measurements by MRI volumetric assessment and hematoxylin and eosin staining are strongly correlative.

Quantitative real-time polymerase chain reaction

To assess the effects of therapeutic intervention on early inflammation, q-PCR was performed for mRNA of inflammatory mediators. The mice were anesthetized, euthanized, and perfused with 30 mL PBS via transcardiac puncture at 4 h after ICH. The brains were sectioned mid-sagittally, flash frozen at −20°C, and stored at −80°C. RNA was extracted from pulverized frozen hemispheres using the PerfectPure RNA Tissue Kit (5 PRIME, Gaithersburg, MD), quantified using a Bio-Rad SmartSpec 3000 Spectrophotometer (Bio-Rad, Hercules, CA), and reverse transcribed to cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) with MultiScribe reverse transcriptase and random primers. The levels of mRNA expression were determined with an ABI 7300 Sequence Detection Software system (Applied Biosystems), using 100 ng cDNA per reaction, adding Taqman Universal PCR master mix and TaqMan Assays-on-Demand
Gene Expression primer/probe sets (all from Applied Biosystems) for the murine cytokines. Relative mRNA quantification was calculated using the 2^(-ΔC_T) method (Livak and Schmittgen, 2001). The threshold cycle number (Ct) of the target gene for each sample was normalized using a housekeeping gene (endogenous 18S), and calibrated to the control samples (uninjured animals). Final results were expressed as fold changes over uninjured animals.

Immunohistochemistry: Fluoro-Jade B staining and F4/80 staining

To assess the effects of therapeutic intervention on early inflammation, immunohistochemical staining was performed for Fluoro-Jade B (Schmued and Hopkins, 2000) (a marker of degenerating neurons), and F4/80 (a marker for microglia), after ICH. The mice were anesthetized, euthanized, and perfused with 30 mL PBS via transcardiac puncture at either 4 h or 24 h after ICH. Sagittal sections (40 μm) were cut on a vibratome and collected in cryoprotectant solution containing ethylene glycol, sucrose, and sodium phosphate. Every eighth section was mounted onto a charged slide.

For assessment of neuronal degeneration, the slides were stained with Fluoro-Jade B and immersed in 100% ethanol for 3 min, followed by 1 min in 70% ethanol, and 1 min in distilled water. The slides were then transferred to a solution of 0.06% potassium permanganate for 15 min, followed by a 1-min rinse in distilled water. The slides were then stained in 0.001% Fluoro-Jade B solution (Histochem, Jefferson, AR) prepared in 0.1% acetic acid for 30 min, and the slides were rinsed for 1 min in distilled water three times. The slides were then dried overnight in the dark. The following day, the slides were cleared by immersion in xylene and cover-slipped with DPX (Fluka, Milwaukee, WI).

For microglia staining, F4/80 immunohistochemistry was performed on brains prepared and cut as described above. Free-floating sections were incubated in 1% H2O2 for 5 min, then transferred to 0.1% saponin for 1 h. Next the sections were incubated for 30 min in 10% goat serum, followed by two successive blocking steps with avidin and biotin for 15 min each. Monoclonal rat anti-mouse F4/80 (MCA497R; Serotec, Raleigh, NC) was applied overnight at 4°C with a dilution of 1:10,000. After washing with PBS, biotinylated goat anti-rat IgG secondary antibody (1:333; Vector Laboratories, Inc., Burlingame, CA) was applied for 20 min, followed by avidin-biotin-peroxidase complex treatment for 12 min (ABC kit; Vector Laboratories, Inc.). Staining was visualized with diaminobenzidine (DAB; Vector Laboratories, Inc.). The sections were mounted onto slides and allowed to dry overnight. Following immunostaining, all sections were counterstained with hematoxylin (Fisher Scientific, Fair Lawn, NJ) for 4 min. After dehydration the sections were cover-slipped using DPX (Fluka, Milwaukee, WI).

Statistical analysis

Rotorod performance and MWM latencies were compared with two-way repeated-measures analysis of variance with day as the repeated variable. The F values were calculated, and if the probability distribution of F with the appropriate degrees of freedom suggested a significant group effect, pairwise testing was performed between groups using Scheffe’s post-hoc method to correct for multiple comparisons. The numbers of Fluoro-Jade and F4/80 cell counts were compared between groups using the Mann-Whitney U statistic. Statistical significance was set at p < 0.05. All values were expressed as mean ± standard error of the mean (SEM) and were performed using JMP software (v7.0.1; SAS Institute Inc., Cary, NC).

Results

Nesiritide improves functional outcome after brain injury

Mice received saline, low-dose, or high-dose nesiritide (8 μg/kg; n = 8/group) after TBI. Testing of vestibulomotor function as assessed by rotord performance demonstrated that high-dose nesiritide administration provided a durable improvement in functional outcomes over the 5 days tested. This effect was dose-dependent, as high-dose nesiritide was associated with significantly better rotord performance than saline- or low-dose-treated animals (p < 0.001; Fig. 2).

We next extended our results to a murine model of ICH by randomizing mice to receive either saline or nesiritide (8 μg/kg) via tail vein injection at 30 min and 4 h (n = 8/group) after injury. Testing of vestibulomotor function as assessed by rotord latency demonstrated that nesiritide administration provided a durable improvement in functional outcomes over the 5 days tested (p < 0.01; Fig. 3) compared to mice receiving saline. This effect does not appear related to hemorrhage volume, as MRI at 4 h post-injury did not reveal any difference in lesion volume (25.0 ± 0.5 versus 21.0 ± 0.3 mm3) for ICH + BNP versus ICH + saline, respectively; n = 5/group; Fig. 4). Thus our data suggest that administration of nesiritide had beneficial effects across several independent paradigms of brain injury.
Over the 7 days of testing (*p < 0.05 nesiritide versus saline). Given nesiritide demonstrated significantly longer latencies over the 5 days of testing (*p < 0.05 nesiritide versus saline).

FIG. 2. Rotorod latencies over consecutive days after traumatic brain injury (TBI) in mice given nesiritide (2 μg/kg [upward-pointing triangles] or 8 μg/kg [downward-pointing triangles]) or saline by tail vein injection at 30 min and 4 h after injury. Mice given 8 μg/kg nesiritide demonstrated significantly longer latencies over the 5 days of testing (*p < 0.05 nesiritide versus saline).

One possible explanation for the beneficial effects of nesiritide was that treatment was associated with a reduction in intracranial hypertension due to its natriuretic effects. To address this possibility, a separate cohort of mice was subjected to TBI (n = 5/group) and randomized to receive either saline or nesiritide (8 μg/kg) via tail vein injection at 30 min and 4 h after injury. Due to the short half-life of nesiritide, serum sodium was measured at 3 and 6 h in both groups and found to be similar at both time points (3 h: 144.6 ± 0.7 mmol/L versus 145 ± 0.7 mmol/L for TBI + saline versus saline).

FIG. 3. Rotorod latencies over consecutive days after intracerebral hemorrhage in mice given nesiritide (8 μg/kg) or saline by tail vein injection at 30 min and 4 h after injury. Mice given nesiritide demonstrated significantly longer latencies over the 7 days of testing (*p < 0.05 nesiritide versus saline).

Effects of nesiritide on cerebral blood flow
To determine the extent to which the neuroprotective effects of nesiritide are due to augmentation of CBF after acute CNS injury, laser doppler blood flow studies were performed in mice after injury with TBI or ICH following administration of saline or nesiritide (8 μg/kg). We have previously demonstrated that despite the dynamic range of cerebral blood flow seen immediately following injury, there is universal hypoperfusion by 20 min (Wang et al., 2007b); therefore we chose to begin monitoring via laser doppler at 25 min after injury. In the ICH paradigm (n = 5/group), although CBF was markedly depressed in the injured hemisphere, no difference in laser doppler flow was measured at either 30 min or 4 h after injury. However, nesiritide treatment was associated with a significant augmentation of CBF after injury in the TBI animals, although this effect was not noted at 4 h (n = 5/group; 92.7 ± 17.2% versus 48.7 ± 12.6% change for TBI + saline, respectively; *p < 0.05; Fig. 6).

Nesiritide reduces central nervous system inflammation
As glial activation and neuroinflammatory responses may exacerbate the development of cerebral edema and secondary brain injury, we next sought to determine whether nesiritide was exerting immunomodulatory effects on the CNS. Quantitative mRNA PCR was performed following ICH for inflammatory cytokines in mice that received nesiritide (8 μg/kg) or saline injection at 30 min and 4 h after injury (n = 5/group). Although endothelium-derived nitric oxide (eNOS) mRNA levels were no different between groups, TNF-α and IL-6 mRNA were significantly reduced at 4 h post-injury in the ipsilateral hemispheres of mice receiving nesiritide (TNF-α: 3.86 versus 76.78 ± 18.99 fold change for ICH + BNP versus ICH + saline, respectively; *p < 0.01); IL-6: 10.95 ± 1.99 versus 42.29 ± 15.26 fold change for ICH + BNP versus ICH + saline, respectively; *p < 0.05; Fig. 7).
To determine if the upregulation of inflammatory cytokines was related to an increase in microglial activation, we performed immunohistochemistry with F4/80 staining, which identifies cells of macrophage lineage such as microglia, after ICH in the hippocampi of mice that received nesiritide (8 μg/kg) or saline injection 30 min and 4 h after injury (n = 6/group/time point). At 4 h post-injury the number of cells staining positive for F4/80 were similar in the contralateral hippocampi, but reduced in the ipsilateral hippocampi of mice receiving nesiritide (ipsilateral hippocampus: 5.53 ± 0.53 versus 7.89 ± 0.26 cells/10⁶ mm³ for ICH + BNP versus ICH + saline, respectively [p < 0.05]; contralateral hippocampus: 3.60 ± 0.79 versus 4.68 ± 0.65 cells/10⁶ mm³ for ICH + BNP versus ICH + saline, respectively). The number of cells staining with F4/80 at 24 h after ICH was increased in all hippocampi compared to the 4-h time point (p < 0.05). Furthermore, F4/80-positive cells at 24 h were significantly reduced in bilateral hippocampi of mice receiving nesiritide compared to the same hippocampi of mice receiving saline (ipsilateral hippocampus: 7.13 ± 0.85 versus 11.5 ± 1.46 cells/10⁶ μm³ for ICH + BNP versus ICH + saline, respectively [p < 0.05]; contralateral hippocampus: 3.48 ± 0.43 versus 7.25 ± 0.53 cells/10⁶ μm³ for ICH + BNP versus ICH + saline, respectively [p < 0.01]; Fig. 8).

To determine if increases in inflammatory cytokines and microglial activation were ultimately related to neuronal degeneration, we performed immunohistochemistry with Fluoro-Jade B, which identifies dead and injured neurons, at

**FIG. 4.** Magnetic resonance images demonstrating similar hemorrhage volumes 4 h after intracerebral hemorrhage in mice given nesiritide (8 μg/kg; A) or saline (B) by tail vein injection at 30 min and 4 h after injury. Though nesiritide increases cerebral blood flow, it does not increase hemorrhage volume.
24 h after ICH in mice that received nesiritide (8 μg/kg) or saline by tail vein injection at 30 min and 4 h after injury. We found a significant reduction in Fluoro-Jade B-positive neurons in the contralateral hippocampus of mice receiving nesiritide compared to those receiving saline (24.25 ± 6.05 versus 108 ± 32.34 cells/10^6 μm^3 for ICH + BNP versus ICH + saline, respectively [^p<0.05]; Fig. 9).

Discussion

In the current study, we demonstrate that administration of exogenous human recombinant BNP (nesiritide) improves functional outcome and reduces histological evidence of neuronal injury in murine models of TBI and ICH. These neuroprotective effects were associated with an augmentation of CBF and reduced neuroinflammatory responses, suggesting that nesiritide may represent a viable, novel therapeutic strategy. Nesiritide was approved by the FDA in 2001 for the treatment of congestive heart failure, and has pluripotent properties in advanced heart failure, including lowering left ventricular filling pressures, neurohormonal effects, enhanced post-injury ventricular remodeling, and improved cardiac myocyte relaxation (Burger et al., 2002; Clarkson et al., 1995; Publication Committee for the VMAC Investigators, 2002; Sakata et al., 2001; Tamura et al., 2000; Yancy et al., 2004).

Although initially identified in the porcine brain, BNP is found primarily in the heart, and is a clinically useful marker of left ventricular distension in the setting of congestive heart failure. Furthermore, multiple studies have demonstrated that BNP is elevated following ischemic stroke and TBI, even in the absence of cardiac injury. In addition, elevations in natriuretic peptides such as BNP have been linked to cerebral salt-wasting syndromes following TBI (Lu et al., 2008), and subarachnoid hemorrhage (McGirt et al., 2004). However, the consistent finding that BNP is elevated after diverse forms of acute CNS injury (including trauma, ICH, and stroke), and that its upregulation in the CSF is independent of changes in serum sodium or cardiac pathology, suggest that BNP may also play an adaptive role in the injured CNS (Kirchhoff et al., 2006; Powner et al., 2007).
One mechanism by which BNP may exert beneficial effects after acute brain injury is by augmenting CBF. This is especially true in the setting of TBI, where post-traumatic cerebral hypoperfusion has been linked to an exacerbation of brain injury (Hlatky et al., 2003), through impairment of autoregulation (i.e., the ability of an organ to maintain constant tissue blood flow despite changes in perfusion pressure), and an inability of pial arterioles to respond to normal changes in \( P_{aco_2} \) and \( P_{ao_2} \) (Wei et al., 1980). Interestingly, in mice injured with ICH, though there was a profound decrease in CBF by laser doppler flowmetry, we did not demonstrate any difference in CBF with nesiritide treatment, despite finding an improvement in outcome. Presumably this is due to the lack of the existence of a perihematomal penumbra in this disease state (Fainardi et al., 2008; Orakcioglu et al., 2008), but may
also be related to the doppler probe being unable to differentiating between hematoma and brain parenchyma.

Although the exact mechanisms by which BNP modulates CBF have not been described, it is known to modulate systemic blood pressure, blood flow to other vital organs (kidneys) and the sympathetic nervous system, and perhaps most interestingly, the renin-angiotensin system (McGrath et al., 2005). In the brain, angiotensin appears to cause receptor-mediated vasoconstriction, among diverse other effects (Saa-vedra, 2005). By inhibiting this effect, BNP may allow an overall increase in CBF when the angiotensin system is upregulated after injury. Increasing evidence suggests that the renin-angiotensin system plays a role in neuronal injury after ischemia, and the modification of this system may result in improved cerebrovascular physiology and improved neurological outcomes (Ito et al., 2001, 2002). Moreover, it appears that modulation of the renin-angiotensin system itself may confer some level of neuroprotection after cerebral ischemia, beyond the modulation of blood flow (Zhou et al., 2005).

In addition to any direct effects on CBF, BNP may also improve outcomes by modulating neuroinflammatory responses, as is more likely the case in ICH. Acute CNS injury is associated with microglial and astrocytic activation, as well as the release of reactive oxygen species and inflammatory mediators. In particular, proinflammatory cytokines such as IL-6 and TNF-α have been suggested to play an important role in early events mediating blood–brain barrier breakdown and subsequent development of cerebral edema (Ramilo et al., 1990). Multiple studies have demonstrated that elevated levels of inflammatory cytokines, such as TNF-α and IL-6, predict secondary brain injury and poor long-term outcome after TBI (Minambres et al., 2003; Woiciechowsky et al., 2002). Consistent with prior work (James et al., 2008a; Wang et al., 2007a), we found robust upregulation of TNF-α and IL-6 RNA in injured brain, which was attenuated by treatment with nesiritide. This was associated with a concurrent reduction in the number of F4/80-positive microglia and Fluoro-Jade B-positive neurons in bilateral hippocampi following injury, as well improved short- and long-term neurological outcomes. Although these effects are consistent with prior data demonstrating that natriuretic peptides may oppose inflammation (Konig et al., 2007; Ma et al., 2004; Meirovich et al., 2008; Vesely and de Bold, 2009), there are few data on its role in the human brain.

Finally, it is interesting that despite improving CBF and attenuating cytokines, an increase in eNOS transcription was not demonstrated. Because cerebrovascular tone and blood flow are mediated in part by eNOS (Morikawa et al., 1994; Yamada et al., 2000), the beneficial effects of BNP agonists on post-traumatic cerebral perfusion could be due to upregulation of eNOS; however, there are several mechanisms by which BNP can enhance eNOS activity without affecting RNA levels (Yemisci et al., 2008). As an example, HMG-CoA reductase inhibitors (statins) have been demonstrated to enhance eNOS activity acutely through post-translational modification, increasing NO generation by enhancing phosphorylation of eNOS by the protein kinase Akt, but not affecting mRNA levels (Luo et al., 2000). Our results are also consistent with a report by Kureishi and colleagues (Kureishi et al., 2000), who found that statins could produce a very rapid improvement in endothelial function that is independent of changes in eNOS mRNA levels via similar pathways.

Although not the main hypothesis of this study, we found neurocognitive effects after ICH in mice as evidenced by impaired performance on the MWM. These cognitive deficits were associated with histological evidence of hippocampal injury. Unlike TBI, in which cognitive deficits are well described, ICH is traditionally thought of as a local phenomenon. Our findings of microgliosis and neuronal injury in the contralateral hemisphere, and hippocampal pathology in areas remote from the hemorrhagic lesion, are consistent with recent articles demonstrating contralateral hemispheric changes and injury after ICH in pre-clinical models (Mun-Bryce et al., 2004, 2006; Nguyen et al., 2008); however, we could find no published data directly addressing the issue of long-term neurocognitive changes after primary ICH in humans. In light of these findings and the evolving understanding of the mechanisms of secondary injury following hematoma formation, it is reasonable to assume that similar impairments might exist in clinical populations.

Several limitations of this study should be addressed. First, augmentation of CBF by administration of BNP may only partially explain its neuroprotective effects. It is likely that BNP exerts additional effects, resulting in decreased recruitment of hematogenous monocytes and activation of endogenous microglia. The exact mechanisms by which this occurs remain to be elucidated. Although both TBI and ICH may have common pathways of glial activation, cerebral edema, and secondary neuronal injury, it would be important to define the patient population for whom administration of BNP might be most appropriate. Given the association with adverse effects such as renal injury, careful determination of the likelihood of these adverse consequences in patients with acute CNS injury is required. For example, the antihypertensive effect of BNP analogues may be more appropriate in the setting of ICH, where patients are often hypertensive and blood pressure control is a priority. Finally, the dose of nesiritide utilized in this study is well above that currently approved by the FDA for use in humans. Thus a full dose-response curve will need to be determined prior to any attempts at translating our findings into the clinical arena.

Despite these limitations, our results suggest that BNP may play a protective role in the setting of acute brain injury, and thus may represent a novel therapeutic strategy. In our preclinical paradigms of TBI and ICH, administration of endogenous BNP was well tolerated and associated with durable functional and histological improvements. Although our data suggest that the benefit of nesiritide may be in part mediated by its vasoactive and anti-inflammatory properties, further studies are needed to fully elucidate its mechanism of action and to determine its therapeutic potential for acute CNS injury.

Acknowledgments

This study was made possible through funding from the FAER Mentored Research Training Grant (M.L.J.).

Author Disclosure Statement

No competing financial interests exist.

References


Address correspondence to:
Michael L. James, M.D.
Duke University Medical Center 3094
Durham, NC 27710
E-mail: james040@mc.duke.edu
This article has been cited by:


